Manufacturing Plants Under Scrutiny By Justice Department

Source: PharmaManufacturing.com

Jun 10, 2013

Forbes

After numerous violations and recalls in both the US and abroad, the United States Department of Justice (DOJ) has promised to take an "especially hard look" at plants to ensure the safety and purity of prescription drugs. Though the FDA continues to have a key role in pharma investigations and regulations, the DOJ will be taking a more active role following the False Claims Act. Read the full story.